kogenate fs
bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.
kogenate fs
bayer new zealand limited - octocog alfa 2000 [iu] (recombinant factor viii) - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.
kogenate fs
bayer new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.
kogenate fs
bayer new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.
kogenate fs
bayer new zealand limited - octocog alfa 3000 [iu] (recombinant factor viii) - injection with diluent - 3000 iu - active: octocog alfa 3000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.
advate
takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).advate does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand disease.
helixate nexgen
bayer ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).this preparation does not contain von willebrand factor and is therefore not indicated in von willebrand's disease.
kovaltry
bayer ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.
advate
takeda new zealand limited - octocog alfa 1000 [iu]; - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.
advate
takeda new zealand limited - octocog alfa 1500 [iu]; - injection with diluent - 1500 iu - active: octocog alfa 1500 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.